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We fully agree with Burhan et . Fortunately, the majority of patients who receive and finish the treatment for drug-susceptible TB will respond completely to treatment We are fully aware that full pharmacokinetic (PK) analysis is costly and difficult and that breakpoints are more frequently determined than actual MICs, but to be able to answer the question of whether TB drug concentrations influence clinical outcome, a strategy that assesses drug exposure (AUC) closely related to a full PK analysis should be considered.
Limited-sampling strategies, using only 2 to 3 samples to predict AUC values with great accuracy and precision, may solve the problem of inadequate drug exposure assessment by C2 h monitoring 6 . Dried blood spot sampling, which is less expensive and more convenient for both patients and research teams, may help to collect the samples needed for predicting
Strategy to limit sampling of antituberculosis drugs 91 AUC values 7 . The combination of limited-sampling strategies, dried blood spot analysis, and measuring actual MICs would give the information needed to deter-mine the relation between TB drug concentrations and clinical outcome 8 . In conclusion, we encourage investigators setting up clinical trials of TB patients to abandon classical C2 h monitoring and replace it with full PK monitoring or limited sampling.
